Native CRISPR-Cas-Mediated Genome Editing Enables Dissecting and Sensitizing Clinical Multidrug-Resistant *P. aeruginosa*

**Authors**
Zeling Xu, Ming Li, Yanran Li, ..., Patrick C.Y. Woo, Hua Xiang, Aixin Yan

**Correspondence**
xiangh@im.ac.cn (H.X.), ayan8@hku.hk (A.Y.)

**In Brief**
Xu et al. develop an efficient genome-editing technique in genetically recalcitrant clinical and environmental *P. aeruginosa* strains by exploiting their endogenous type I-F CRISPR-Cas system. Employing the technique, they identify underlying resistance mechanisms of an epidemic MDR genotype, PA154197, efficiently and develop anti-resistance strategies based on collateral sensitivity.

**Highlights**
- Endogenous type I-F CRISPR-Cas is repurposed for genome editing in MDR *P. aeruginosa*
- Mutant lines reveal key MDR determinants and extensive synergy in a clinical isolate
- Clinical strain PA154197 displays collateral sensitivity to small cationic peptidomimetics
- Small cationic peptidomimetics sensitize PA154197 cells to antibiotics
Native CRISPR-Cas-Mediated Genome Editing Enables Dissecting and Sensitizing Clinical Multidrug-Resistant \textit{P. aeruginosa}

Zeling Xu,1,6 Ming Li,2,6 Yanran Li,3 Huihui Cao,1,7 Hua Xiang,3∗ and Aixin Yan1,8,∗

1School of Biological Sciences, The University of Hong Kong, Pokfulam Road, Hong Kong SAR, China
2State Key Laboratory of Microbial Resources, Institute of Microbiology, Chinese Academy of Sciences, Beijing 100101, China
3CAS Key Laboratory of Separation Science for Analytical Chemistry, Dalian Institute of Chemical Physics, Chinese Academy of Sciences, Dalian 116023, China
4Institute of Scientific and Industrial Research, Osaka University, Osaka 567-0047, Japan
5Department of Microbiology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China
6These authors contributed equally
7Present address: Department of Microbiology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China
8Lead Contact
∗Correspondence: xiangh@im.ac.cn (H.X.), ayan8@hku.hk (A.Y.)
https://doi.org/10.1016/j.celrep.2019.10.006

SUMMARY

Despite being fundamentally important and having direct therapeutic implications, the functional genomics of the clinical isolates of multidrug-resistant (MDR) pathogens is often impeded by the lack of genome-editing tools. Here, we report the establishment of a highly efficient, \textit{in situ} genome-editing technique applicable in clinical and environmental isolates of the prototypic MDR pathogen \textit{P. aeruginosa} by harnessing the endogenous type I-F CRISPR-Cas systems. Using this approach, we generate various reverse mutations in an epidemic MDR genotype, PA154197, and identify underlying resistance mechanisms that involve the extensive synergy among three different resistance determinants. Screening a series of “ancestor” mutant lines uncovers the remarkable sensitivity of the MDR line PA154197 to a class of small, cationic peptidomimetics, which sensitize PA154197 cells to antibiotics by perturbing outer-membrane permeability. These studies provide a framework for molecular genetics and anti-resistance drug discovery for clinically isolated MDR pathogens.

INTRODUCTION

Antimicrobial resistance (AMR) is imposing an alarming threat on global public health. Particularly challenging are those “ESKAPE” pathogens that constitute the major sources of nosocomial infections with extraordinary drug resistance (i.e., \textit{Enterococcus} spp., \textit{Staphylococcus aureus}, \textit{Klebsiella} spp., \textit{Acinetobacter baumannii}, \textit{Pseudomonas aeruginosa}, and \textit{Enterobacter} spp.). Among them, \textit{Pseudomonas aeruginosa} is recognized as a prototypical multidrug-resistant (MDR) pathogen owing to both its intrinsic resistance to a variety of antimicrobials and its enormous capacity to develop acquired resistance during antibiotics chemotherapies (Oliver et al., 2015; Poole, 2011; Santajit and Indrawattana, 2016; Stover et al., 2000). Remarkably, in recent years, MDR international high-risk clones of \textit{P. aeruginosa} have emerged and caused worldwide outbreaks (Oliver et al., 2015). Hence, it is of paramount importance to deeply understand the resistance mechanisms of these clones and develop anti-resistance treatment strategies. However, these studies are frequently impeded because of the lack of genetic-editing tools in the clinical \textit{P. aeruginosa} genotypes.

\textit{P. aeruginosa} is a ubiquitous pathogen capable of causing a wide array of acute and chronic infections. The species is notorious for its unusually large (ca. 6.4 Mbp) genome and extraordinarily diverse genotypes (Silby et al., 2011). As a result, genetic tools established in the model strains, such as PAO1 and PA14, are often inapplicable in the clinical, environmental, and biotechnological strains of interest. Moreover, clinical MDR clones often contain a complex set of resistance markers originating from both chromosomal gene mutations and transferable elements (Cabot et al., 2012; Hocquet et al., 2003), further limiting the conventional antibiotic-resistance-marker-based genetic manipulations. On the other hand, studies have indicated that the genetic background of resistant strains and epistasis among different resistant mutations plays an important role in the resistance levels of the strains and affects the effectiveness of antibiotic chemotherapies (Moura de Sousa et al., 2017; Vogwill et al., 2014, 2016). Hence, it is highly desirable to develop genome-editing techniques compatible with the genotypes of the strains of interests and to characterize AMR in the native genetic background of clinical strains.

In addition to being recognized as a prototypical MDR pathogen, \textit{P. aeruginosa} is also an important model organism for understating CRISPR-Cas functions, especially the most widespread type I CRISPR-Cas system (van Belkum et al., 2015). To exert its functions in the adaptive immune process in bacteria, the Cas proteins specifically bind to and cleave the invader DNA.
based on Watson-Crick base pairing between a small CRISPR RNA (crRNA) and its DNA target (Barrangou et al., 2007; Hille et al., 2018). Conceivably, by modifying the sequence of the RNA guide, the Cas nucleases can be reprogrammed to cleave a specific genomic site and be exploited for genome editing upon a repair template is provided (Jinek et al., 2012). Phylogenetic analysis has revealed that CRISPR-Cas systems are widely distributed in global AMR. P. aeruginosa isolates with ~70% of them belonging to the I-F subtype (van Belkum et al., 2015). In recent years, repurposing the broadly distributed native CRISPR-Cas systems is emerging as a new CRISPR-based genome-editing strategy in prokaryotes. For instance, the native type I-B CRISPR-Cas system was harnessed for genome editing in the medically and industrially important species Clostridium tyrobutyricum and Clostridium pasteurianum, which frequently suffer from a poor DNA homeostasis and have a low genome-editing efficiency using the traditional allelic exchange or the heterologous CRISPR-Cas9 system (Pyne et al., 2016; Zhang et al., 2018). The endogenous type I-E CRISPR-Cas system was successfully repurposed for genome editing in the commensal bacterium Lactobacillus crispatus, which was formerly genetically recalcitrant (Hidalgo-Cantabrana et al., 2019). However, there has been no report about exploitation of native CRISPR-Cas systems for genome editing and functional genomics in the prototypic pathogen P. aeruginos.a.

Previously, we have isolated an epidemic MDR P. aeruginos.a clinical strain, PA154197, that shares a clonal complex with two international cystic fibrosis (CF) isolates and displays a comparable resistance profile to the high-risk clone ST175 (Cao et al., 2019). Employing the allelic exchange and the heterologous CRISPR-Cas9-based method failed to deliver desired mutations for resistance characterization in this strain. As in the majority of clinical and environmental isolates of P. aeruginos.a, PA154197 is found to contain a native type I-F CRISPR-Cas loci. Hence, in this study, we use PA154197 as a model to explore the native type I-F CRISPR-Cas-based genome editing in a clinical MDR P. aeruginos.a genotype and its exploitation in the functional genomics of MDR. A highly efficient, one-step (for non-essential gene allele) or two-step insert-delete (In-Del) (for essential gene allele or inefficiently targeted genome site) genome-editing technique was successfully developed. The editing pipeline was readily applicable in additional clinical and environmental P. aeruginos.a strains tested that contain the endogenous type I-F CRISPR-Cas system. Employing the technique, we unveiled the extraordinary resistance capacity of PA154197 and developed an advanced treatment strategy against this clinical MDR isolate. These studies provided a framework for understanding and control of clinical resistant pathogens.

RESULTS

Functionality of the Native Type I-F CRISPR-Cas Locus in PA154197

Analysis of the CRISPR loci in PA154197 identified the signature cas8β gene and the unique cas2-cas3 fusion (Figure 1A) (Richter et al., 2012), indicating that the loci encode a typical type I-F CRISPR-Cas system. The cas operon of the system was found to be sandwiched by two convergent CRISPR arrays with 4 and 10 spacers, respectively. Their consensus repeat sequence differs by only one nucleotide, and their spacers are nearly identical in size (32 bp) (Figure 1A). In addition, a number of spacers show significant homology to phage or putative prophage sequences (data not shown), implying the adaptive immune activity of the endogenous CRISPR-Cas system.

To harness the system for genome editing, we first assessed its genome-targeting activity. We selected mexB as the target gene for this purpose, which encodes the inner-membrane component of the housekeeping efflux pump MexAB-OprM. Previous studies have revealed that the canonical target of the type I-F CRISPR-Cas system is 5'-protospacer-GG-3' with 5'-GG-3' serving as the protospacer adjacent motif (PAM) sequence (Cady et al., 2012; Richter et al., 2014). Noticeably, because the crRNA guides the base pairing with the complement 5'-protospacer-GG-3' sequence in the target, earlier studies defined 5'-GG-3' as the PAM. However, it was recently proposed to follow the guide-centric (5'-CC-3'), rather than the target-centric (5'-GG-3'), terminology (Leenay and Bei sel, 2017). Therefore, hereafter the PAM is described as 5'-CC-3'. Thus, an internal 32-bp nucleotide preceded by a 5'-CC-3' PAM corresponding to the C74-C105 region in mexB was selected as the target (PAM protospacer). To achieve specific targeting to this genomic region by the native CRISPR-Cas machinery in PA154197 cells, an artificial mini-CRISPR encompassing the selected 32-bp internal sequence flanked by two 28-bp repeats was assembled. To construct a plasmid-based tool enabling expression and delivery of the mini-CRISPR into PA154197 cells, a strong promoter Ptat (Shah, 2014) was selected to drive the expression of the mini-CRISPR and the expression cassette was cloned into the pMS402 vector upstream of the lux genes (Olsen et al., 1982). Along with the kanamycin resistance marker on the vector, this plasmid tool allows an antibiotic-luminescence dual selection of the transformants (Figure 1B). The resulting plasmid pAY5233 is termed the targeting plasmid in the editing method we developed (Figure 1B). Transformation of pAY5233 into PA154197 cells yielded no transformants recovery compared with the high transformation efficiency of the control plasmid pAY5211, which lacks the mini-CRISPR array (Figure 1C), implying the occurrence of the detrimental chromosome cleavage in the pAY5233-containing cells. This result verified that the native CRISPR-Cas system in PA154197 is active to interfere genomic DNA.

Harnessing the Native Type I-F CRISPR-Cas System to Delete the AMR Gene mexB

To exploit the system for gene deletion (ΔmexB as an example), we then assembled a 1-kb donor sequence consisting of 500-bp upstream and 500-bp downstream homologous arms of mexB and inserted it into pAY5233 to yield pAY5235 (Figure 1D), which is termed the editing plasmid in our method. The transformation recovery rate of pAY5235 into PA154197 cells was significantly increased compared to that of the targeting plasmid pAY5233 (Figure 1C), suggesting the occurrence of homologous recombination by the provision of the repair donor. Since the plasmid tool contains a Ptat-driven lux cassette, luminescence was utilized to assist in the screening of positive clones. Eight luminescent
colonies were selected for validation and four colonies showed the desired, scarless, and precise mexB deletion (~3 kb) in the chromosome (Figures 1E and 1F).

The success rate increased to more than 90% when the size of the desired gene deletion was decreased to ~1 kb (Figures S1A and S1B), which is the average size of prokaryotic genes.
Furthermore, the plasmid tool can be readily cured following culturing of the edited cells in the absence of the antibiotic (kanamycin) pressure overnight (Figure S2), suggesting the feasibility of multiple rounds of genome editing using the programmable editing plasmid. Further studies revealed that the technique was readily applicable in two additional type I-F CRISPR-containing clinical and environmental P. aeruginosa strains, PA150567 and Ocean-100 (Figure S1C), demonstrating the applicability of the technique in a broad range of P. aeruginosa strains isolated from different sources.

Simultaneous Overexpression of the MexAB-OprM and MexEF-OprN Efflux Pumps Constitutes the Major Resistant Determinants in PA154197

Employing the established genetic-editing technique, we first constructed ΔmexB, ΔmexF, and ΔmexH mutants and examined the contribution of three multidrug efflux pumps MexAB-OprM, MexEF-OprN, and MexGHI-OpmD to the resistance profile of PA154197, which were shown to be overexpressed by transcriptome analysis (Cao et al., 2019). ΔmexB led to a downshift of minimum inhibitory concentrations (MICs) of all antipseudomonal antibiotics tested (Figure 2; Table S1). ΔmexF led to greater fold changes occurring to antipseudomonal β-lactams and penicillin-β-lactamase inhibitor combinations, i.e., CAR (> 128-fold), CAZ (8-fold), MEM (> 32-fold), ATM (64-fold decrease), Tzp (64-fold), than to the fluoroquinolones LVX (2-fold) and CIP (2-fold). ΔmexF led to a downshift of MICs of antipseudomonal fluoroquinolones (FQs), i.e., LVX (2-fold) and CIP (4-fold), which is consistent with the substrates profile of the two pumps revealed by ectopic overexpression of the genes in laboratory strain PAO1 (Köhler et al., 1997). Unexpectedly, deletion of mexH did not lead to any detectable difference in the MICs of all the antibiotics and antimicrobial agents tested (Figure 2; Table S1). Further deletion of mexH in the ΔmexB ΔmexF strain background showed no change in MIC either (data not shown), suggesting that the MexGHI-OpmD pump does not contribute to the resistance development in PA154197.

We further constructed ΔmexB ΔmexF double deletion to investigate the additive effect of the two pumps, if any. MICs of antipseudomonal β-lactams in the double-deletion strain were similar to those in the ΔmexB single-deletion strain, suggesting that β-lactam resistance was largely caused by the MexAB-OprM pump in PA154197. Remarkably, MICs of antipseudomonal FQs were found to be dramatically decreased in the double-deletion cells compared to those in the ΔmexB and ΔmexF single-deletion cells (Table S1). The MIC fold change of the two FQs (32-fold) was much greater than the multiply of the MIC fold change caused by ΔmexB (2-fold) and of ΔmexF (2–4-fold) alone, suggesting the synergy of the two pumps to expel fluoroquinolones. We next assessed the synergy by calculating the fractional inhibitory concentration index (FICI) (Gonzales et al., 2015) of the ΔmexB ΔmexF combination against the antibiotics tested (Figure 2). The FICI value < 0.5 indicates obvious synergy; a FICI value of 0.5–1.0 indicates partial synergy and a FICI value of 1.0–4.0 indicates indifference. The FICI values of the ΔmexB ΔmexF combination against LVX and CIP were found to be 0.125 and 0.188, respectively, suggesting substantial synergy of the two pumps to expel FQs (Figure 2). Disk diffusion testing showed the similar trend of susceptibility changes in these mutant strains (Figures S3A and S3B). Analysis of growth curves of these strains in the absence of antibiotics suggested that the observed MIC alterations were not caused by growth differences (Figure S3C).

A Two-Step In-Del Strategy to Edit the Essential Gene gyrA Reveals the Third Fluoroquinolone Resistance Determinant in PA154197

Although the ΔmexB ΔmexF double deletion led to a 32-fold downshift of the MICs of LVX (32–1) and CIP (16–0.5), their values...
in this mutant are still higher than in the control strain PAO1 (MIC of both LVX and CIP is 0.25), suggesting the presence of additional FQ resistance determinants in PA154197. A T248C substitution (corresponding to T83I) in the quinolone resistance determinants region (QRDR) (Varughese et al., 2018) of the DNA gyrA gene was identified in PA154197 (Figure S4A). To examine whether this mutation confers further FQ resistance in PA154197, we set out to replace the gyrA gene with that in PAO1, i.e., to construct PA154197 donor lacks the tag sequence but contains the desired PAO1 gene sequence was provided to achieve the gene replacement (Figure S4C). We then employed the two-step In-Del strategy described above to construct the reverse mutation of 8-bp insertion because the 8-bp deletion in mexT was previously described as an nfxC type resistant mutation (Linares et al., 2005; Maseda et al., 2000) is identified in PA154197 (Figure S4C). The mexT gene encodes a transcription activator of the mexEF-oprN efflux system (Figure 4A) (Köhler et al., 1999). An 8-bp deletion in mexT that was previously described as an nfxC type resistant mutation (Linares et al., 2005; Maseda et al., 2000) is identified in PA154197 (Figure S4C). We then employed the two-step In-Del strategy described above to construct the reverse mutation of 8-bp insertion because the nucleotides sequence of the PAM protospacer for the desired editing site in mexT contains two 6-bp repeats, which occluded efficient CRISPR recognition and caused failure of DNA interference (Figures S5A and S5B). The resulting mutant was designated as mexT<sup>PAO1</sup>. Both transcription of mexEF-oprN and the MICs of LVX and CIP in the mexT<sup>PAO1</sup> cells were reduced compared to the wild-type (WT) PA154197 (Table S1), indicating that the nfxC type 8-bp deletion in mexT is responsible for the overexpression of mexEF-oprN. Notably, in several non-MDR genotypes, overexpression of the MexEF-OprN pump by MexT in the nfxC type P. aeruginosa was reported to lead to antagonistic impairment of the MexAB-OprM pump and a hyper-susceptibility to its substrates β-lactams (Figure 4A) (Maseda et al., 2004; Mulet et al., 2011). The fact that the nfxC type mutation-containing PA154197 cells over-produce the MexAB-OprM pump and are resistant to β-lactams suggests that either the mexF G226T mutation or additional compensatory mutation in PA154197 suppressed the MexT-mediated repression of MexAB-OprM (Figure 4A).

Consistent with its role of simultaneously repressing another AMR gene oprD that encodes an outer-membrane (OM) porin protein (Figure 4A), the reverse mutation mexT<sup>PAO1</sup>
also led to a 3-fold-higher transcription of oprD than the PA154197 parent (Figure 4C) and a restored susceptibility to imi-
penem (IPM), whose entry is dependent on the OprD portal (Fig-
ure S3). In the case of another AMR gene, parS, that was pro-
posed to also regulate mexEF-oprN system (Wang et al.,
2013), reverse mutation of a nonsynonymous nucleotide substi-
tution, G1193A, in the gene (Cao et al., 2019) did not lead to any
susceptibility changes to various antibiotics (Table S1), suggest-
ing that this mutation does not contribute to the resistance devel-
opment in PA154197.

Figure 4. Mutations in mexR and mexT Lead to Simultaneous Overexpression of the mexAB-oprM and mexEF-oprN Efflux Pumps
(A) Schematic showing the regulation of mexAB-oprM, mexEF-oprN, and oprD in P. aeruginosa PAO1, nfxC type mutant, and PA154197. Arrows indicate activation, T-shaped arrows indicate repression, dashed T-shaped arrow indicates potential suppression, and bended arrows with different weights upstream of the genes indicate the relative expression levels of the genes in the three cell backgrounds.
(B) Relative expression of mexA and mexB in PA154197 and in PAO1, and in PA154197 and its isogenic mexR<sub>PAO1</sub> mutant measured by qRT-PCR.
(C) Relative expression of mexE, mexF, and oprD in PA154197 and in PAO1, and in PA154197 and its isogenic mexT<sub>PAO1</sub> mutant measured by qRT-PCR. Data are represented as the mean ± SD (n = 3).
See also Figure S4.

Extensive Resistance Synergy and Multiplication Networks Shape the Clinically Significant MDR in PA154197
We next constructed a series of double- and triple-reverse muta-
tions and examined the interplay of the different resistance determinants. Reverse of all three resistance mutations identi-
fied (i.e., gyrA<sub>PAO1</sub>, mexR<sub>PAO1</sub>, and mexT<sub>PAO1</sub>) led to the complete loss of antibiotics resistance and an overall drug sus-
cceptibility profile similar to that of PAO1 (Figure 2; Table S1), confirming that these three genetic mutations underlie the

resistance development in PA154197. FICI values of the gyrA<sub>PAO1</sub>-mexR<sub>PAO1</sub>-mexT<sub>PAO1</sub> triple combination against the LVX and CIP were calculated to be 0.156 and 0.047, respectively (Figure 2), indicating substantial and extensive synergy of all three determinants to confer the hyper FQ resistance in PA154197. FICI values of the series of reverse-mutation combi-
nations against several non-antipseudomonal antibiotics re-
vealed the strong synergy of overproduction of the two pumps to confer TMP (FICI = 0.094) and CHL (FICI = 0.063) resistance as well and partial synergy toward CRO (FICI = 0.625) and TET (FICI = 0.625) resistance in PA154197.

On the other hand, resistance to antipseudomonal β-lactams
including the penicillin-β-lactamase inhibitor combination was almost exclusively dependent on the activity of the MexAB-OprM pump in PA154197. The series of isogenic reverse muta-
tants constructed allowed assessing the relative contribution of
basal-level MexAB-OprM and MexAB-OprM over-production to the β-lactams resistance, which can be calculated with the formulas MIC<sub>mexR<sub>PAO1</sub>/MIC<sub>mexR<sub>PAO1</sub></sub>, and MIC<sub>WT/MIC<sub>mexR<sub>PAO1</sub></sub></sub>
respectively. The results suggested that resistance to the anti-
psuedomonal penicillin CAR was largely conferred by basal-level
MexAB-OprM (64-fold MIC change by basal-level pump versus 2-fold by over-produced pump) (Table S2), whereas resistance to the monobactam ATM was largely contributed by the over-production of the MexAB-OprM pump (16- versus 4-fold) (Table S2). The FQ resistance conferred by the MexAB-OprM pump was also attributed to the over-production of the pump (Table S2). Together, these results illustrated the robust interplay among the various types and levels of resistance determinants in PA154197 to confer clinically significant MDR.

**PA154197 Displays Collateral Sensitivity to Small Cationic Peptidomimetics in a mexT-Dependent Manner**

MDR represents the major obstacle in the therapeutics of *P. aeruginosa* infections. To combat drug-resistant infections, it is necessary to both develop new antibiotics and to potentiate the existing antibiotics and preserve the current antibiotics pipeline. Fortuitously, when we attempted to employ the efflux pump inhibitor phenyl-arginine-beta-naphthylamide (PAβN) to treat PA154197, we found that the strain is fairly sensitive to this compound with a MIC value of 16 (µg/ml) (Figure 5A), much lower than the working concentration of the compound (50 µg/ml) to inhibit the basal-level efflux activity (Lamers et al., 2013). Importantly, we found that PA154197 displays a much higher PAβN susceptibility than the control strain PAO1 (MIC > 128). Further analysis of the series of isogenic mutants that reversed one, two, or all three key resistant determinants revealed that their PAβN susceptibilities were intermediate (MIC = 32–128) compared with the PA154197 parent and the reference strain PAO1. The PAβN susceptibilities profile of these strains was opposite of that of antibiotics (Figure 5A), indicating that stepwise acquisition of resistance mutations against antibiotics rendered PA154197 susceptible to PAβN. This pattern reflected a phenomenon called “collateral sensitivity,” i.e., evolved resistance is costly and resistance mutations to one class of antibiotics may exacerbate susceptibility against other antibiotics or agents (Szybalski and Bryson, 1952). Despite being verified in a series of laboratory-evolved resistant strains of *E. coli* and *P. aeruginosa* (Barbosa et al., 2017; Gonzales et al., 2015; Lázár et al., 2018; Pál et al., 2015; Podnecky et al., 2018; Wambahg et al., 2017), no systematic investigation and collateral sensitivity has been reported in clinical MDR strains. Our data above indicated that PA154197 displayed collateral sensitivity to PAβN. To further investigate this, we also measured the MICs of other classes of antibiotics including aminoglycosides (streptomycin and gentamycin), non-ribosomal peptides (Polymyxin B and colistin), fosfomycin, and the antimicrobial peptide GF-17 against these strains, but found none of them displayed collateral effects against PA154197 (Table S1).

Furthermore, we found that the collateral effect of PAβN against PA154197 is dependent on the mexT gene, as replacing the mexT allele with the PAO1 mexT (mexT<sup>PAO1</sup>) abolished the susceptibility of PA154197 to PAβN (Figure 5A). Similar abolishment of the collateral sensitivity was observed in all mutants containing mexT<sup>PAO1</sup> (Figure 5A). Notably, this effect is independent of the capacity of MexT to activate the mexEF-oprN efflux pump as neither ΔmexF nor ΔmexBΔmexF double deletion abolished the sensitivity of the strain to PAβN. Since MexT also regulates the OM porin gene oprD and PAβN was indicated to also act on the *P. aeruginosa* OM to increase its permeability (Lamers et al., 2013), we speculated that the *mexT*-dependent collateral sensitivity in PA154197 is due to its altered OM features relative to PAO1. To address this, we employed an OM-sensitive probe PI-BactD (Long et al., 2019) to monitor the OM features of PA154197 and PAO1 cells and the cells treated by PAβN. Signals corresponding to PA154197 and PAO1 cells were distinctive in the 2D output graph of the sensor (Figure 5B), suggesting the different physical chemical features of their OM. Furthermore, an obvious signal shift was recorded in the PA154197 population upon PAβN treatment, whereas no signal shift was observed in the PAO1 population in response to the same PAβN treatment (Figure 5B), confirming that the higher susceptibility of PA154197 to PAβN compared to PAO1 was due to the higher susceptibility of its OM to the perturbation by PAβN. Consistent with this, an insertion mutation in the porin gene oprD that potentially perturbs the OM of PA154197 cells further increased the sensitivity of the resulting cells to PAβN (MIC = 8) (Figure 5A). Furthermore, sub-inhibitory concentration of PAβN (7.5 µg/ml) was sufficient to sensitize PA154197 to the bulky, anti-Gram-positive antibiotic vancomycin (MIC = 2) (Table S3), which normally is incapable of crossing the OM of Gram-negative bacteria due to the membrane permeability barrier and hence is inactive to Gram-negative cells. Supplement of Mg<sup>2+</sup>, which stabilizes the OM, reversed this effect, i.e., restored resistance to vancomycin (Table S3).

To further confirm the hyper-sensitivity of PA154197 to small, cationic compounds, we tested and compared the...
sensitivity of PA154197 and PAO1 to another cationic peptidomimetic we developed: (R)-N-(4-(tert-butyl)thiazol-2-yl)-2-chloro-5-(2,6-diaminohexanamido) benzamide (H-31) (Yamaguchi et al., 2017). PA154197 indeed displayed 32-fold lower MIC to H-31 than PAO1 (Table S3). Likewise, supplementing PA154197 and H-31 also led to the downshift of MICs of these antibiotics against the susceptible strain PAO1, but to a much smaller extent, i.e., 1–8-fold (Figure 6; Table S4). Supplementation of the same concentration of PA\textsuperscript{N} and H-31 against PA154197 rendered the collateral sensitivity of the cells to small, cationic peptidomimetics due to OM perturbation.

### PA\textsuperscript{N} and H-31 Potentiate Antipseudomonal Antibiotics against the MDR Strain PA154197

We next exploited the identified collateral effect to treat the clinical MDR strain PA154197. We first examined the MICs of various antibiotics against PA154197 in the presence of sub-inhibitory concentration of PA\textsuperscript{N} (7.5 \(\mu\text{g/mL}\)) and H-31 (2 \(\mu\text{g/mL}\)), respectively. Supplementing PA\textsuperscript{N} and H-31 led to 4–128- and 1–64-fold downshifts of MICs of all the antibiotics tested, respectively, demonstrating that PA\textsuperscript{N} and H-31 potentiate the activities of antibiotics against PA154197 (Figure 6; Table S4). Supplementing the same concentration of PA\textsuperscript{N} and H-31 also led to the downshift of MICs of these antibiotics against the susceptible strain PAO1, but to a much smaller extent, i.e., 1–8-fold (Figure 6; Table S4). Introduction of mex\textsuperscript{T}\textsubscript{PAO1} alleviated the antibiotics potentiation effect of PA\textsuperscript{N} and H-31 against PA154197 (Table S5), further confirming the collateral effect of PA\textsuperscript{N} and H-31 against PA154197 and its genetic dependence on the mex\textsuperscript{T} allele. The sensitivity curve showed that supplementing PA\textsuperscript{N} and H-31 rendered the MDR PA154197 cells susceptible to antibiotics, such as IPM and FOF, and the susceptibility was greater than the PAO1 cells (Figure 7). To further examine the efficacy of collateral agents and antibiotics combinations against the MDR P. aeruginosa cells, we co-administered 7.5 \(\mu\text{g/mL}\) PA\textsuperscript{N} or 2 \(\mu\text{g/mL}\) H-31 with two antibiotics, 4MIC IPM and 4MIC FOF, to PA154197 or PAO1 cell cultures and analyzed their killing kinetics. The combined treatment not only was more effective against the MDR strain PA154197 than against the susceptible strain PAO1 but also displayed an accelerated killing against PA154197 than against PAO1 (Figure S6), demonstrating the applicability of the uncovered collateral sensitivity in anti-resistance interventions against clinical MDR strains.

### DISCUSSION

Due to the difficulty of genetic manipulation in the clinical isolates of resistant pathogens, understanding of their resistance development has been largely based on comparative genomics and heterologous reconstitution in the laboratory model strains (Jia et al., 2017). In this study, we established a single-plasmid-mediated, highly efficient genome-editing technique in the prototypic pathogen P. aeruginosa by harnessing the most common CRISPR-Cas system (type I-F) in the species. Compared with a recently reported heterologous Cas9-based genome-editing method in P. aeruginosa model strains that requires successive transformation of two editing plasmids (Chen et al., 2018), and the conventional two-step allelic exchange method (Choi and Schweizer, 2005), which is more laborious and results in an undesirable flippase recognition target (FRT) scar in the edited site, our method of using a one-step transformation of a single editing plasmid represents a more efficient and cleaner genome-editing technique, especially in those clinical and environmental strains suffering a poor DNA homeostasis. Combined with the two-step In-Del strategy, this technique enabled various non-lethal genetic manipulations in P. aeruginosa cells.

Employing this powerful editing technique, not only the key resistant determinants but also their synergy and multiplication networks underlying the extraordinary antibiotic recalcitrance of PA154197 were identified. Two RND efflux pumps, MexAB-OprM and MexEF-OprN, are simultaneously over-produced and synergize the efflux of FQs, CHL, and TMP in PA154197. Interestingly, previous studies using genetic reconstitution in laboratory strains suggested that there is a lack of multiplicative or synergetic effects between over-expression of multidrug efflux pumps (Bruchmann et al., 2013; Horna et al., 2018; Köhler et al., 1999; Li et al., 2015; Llanes et al., 2004; Riera et al., 2011). Particularly, in the nfxC type P. aeruginosa strains, over-production of MexEF-OprN was found to be antagonistic to the MexAB-OprM pump. (Maseda et al., 2004; Mulet et al., 2011). These results together suggested that clinical MDR P. aeruginosa strains might have developed compensatory mutations to overcome the fitness trade-off of overexpressing more than one of the efflux pumps, which warrants further investigations in the future.

Despite its increasing therapeutic implications in the treatment of drug-resistant pathogens (Barbosa et al., 2017; Lázár et al., 2018; Pál et al., 2015; Podnecky et al., 2018; Szybalski and
Bryson, 1952; Wambaugh et al., 2017), research about collateral sensitivity has largely focused on the laboratory-evolved strain lines that display resistance to specific classes of antibiotics, and little effort has focused on the clinically isolated MDR strains (Imamovic et al., 2018; Jansen et al., 2016). The series of constructed isogenic mutants that mimic the sequential acquisition of the key resistance mutations enabled us to identify the collateral sensitivity of PA154197 to small cationic peptidomimetics due to its compromised OM permeability. Interestingly, a recent study on a set of 60 laboratory-evolved antibiotic-resistant E. coli also revealed a widespread collateral sensitivity of the resistant strains to the OM targeting agent antimicrobial peptides (Lázár et al., 2018). Analogously, in addition to regulating the mexEF multidrug efflux pump, MexT is known to also regulate the porin gene oprD and a series of other genes in P. aeruginosa (Tian et al., 2009). These results suggested that transcription regulators that simultaneously regulate membrane-associated resistance determinants and other membrane homeostasis genes may represent as the common genetic determinants of collateral sensitivity. These findings have important implications in characterizing collateral sensitivity in other Gram-negative resistant pathogens.

Lastly, we found that overexpression (~40-fold higher than in PAO1) of the efflux gene mexH and nucleotide substitution in parS did not contribute to the drug resistance in PA154197. These results suggest that not all genetic variations in resistance genes lead to the development of antibiotic resistance phenotypes, further highlighting the importance and necessity of the targeted functional genomics in the genetic background of clinically resistant pathogens.

**STAR METHODS**

Detailed methods are provided in the online version of this paper and include the following:

- **KEY RESOURCES TABLE**
- **LEAD CONTACT AND MATERIALS AVAILABILITY**
- **EXPERIMENTAL MODEL AND SUBJECT DETAILS**
- **METHOD DETAILS**
  - Plasmid Construction
  - Transformation of PA154197
  - Mutants Screening and Verification
  - Curing of Editing Plasmid
  - Antibiotic Sensitivity Assays
  - Quantitative reverse transcriptase PCR
  - Disk Diffusion Assay
  - Fractional Inhibitory Concentration Index
  - PI-BactD Assay
  - Time-Kill Assay
- **QUANTIFICATION AND STATISTICAL ANALYSIS**
- **DATA AND CODE AVAILABILITY**
SUPPLEMENTAL INFORMATION

Supplemental Information can be found online at https://doi.org/10.1016/j.cellrep.2019.10.006.

ACKNOWLEDGMENTS

We thank Prof. Susumu Yoshizawa and Prof. Kazuhiro Kogure (both from the University of Tokyo) for sharing the ocean-100 strain. We thank Prof. Xuechen Li (Department of Chemistry, The University of Hong Kong) for providing the GF-17 peptide and Dr. Xin Deng (Department of Biomedical Sciences, City University of Hong Kong) for the pMS402 vector. We thank Dr. Zhaoxun Liang (School of Biological Sciences, Nanyang Technological University, Singapore) for his stimulating discussion with us about the manuscript, and Prof. Min Wu (School of Medicine and Health Sciences, University of North Dakota) for proofreading the manuscript. This work was supported by the Hong Kong University Grants Council General Research Fund (HKU1742316 to A.Y.); the Seed Funding for Basic Research Scheme of The University of Hong Kong (201711159278 to A.Y.); the Seed Funding for Strategic Interdisciplinary Research Scheme (HKU 2017 to A.Y.); the National Natural Science Foundation of China (No. 31571283 to H.X.); and the National Transgenic Science and Technology Program (2019ZX08010-003 to M.L.).

AUTHOR CONTRIBUTIONS

Z.X., M.L., H.X., and A.Y. designed the research; Z.X. and Y.L. performed the experiments; H.C. contributed to the bioinformatic analysis; L.M. and Z.C.X. synthesized Pi-BactD and performed the Pi-BactD assay; Y.H., S.Y., and K.N. synthesized and provided H-31; P.C.Y.W. provided clinical PA isolates and participated in the data analysis; and Z.X., M.L., H.X., and A.Y. analyzed the data and wrote the manuscript.

DECLARATION OF INTERESTS

The authors declare no competing interests.

REFERENCES


**STAR METHODS**

**KEY RESOURCES TABLE**

<table>
<thead>
<tr>
<th>REAGENT or RESOURCE</th>
<th>SOURCE</th>
<th>IDENTIFIER</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Bacterial and Virus Strains</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PA154197</td>
<td>This paper</td>
<td>N/A</td>
</tr>
<tr>
<td>PA150567</td>
<td>This paper</td>
<td>N/A</td>
</tr>
<tr>
<td>Ocean-100</td>
<td>Kumagai et al., 2017</td>
<td>N/A</td>
</tr>
<tr>
<td>DH5α</td>
<td>This paper</td>
<td>N/A</td>
</tr>
<tr>
<td>PA154197 mutants, see Table S6</td>
<td>This paper</td>
<td>N/A</td>
</tr>
<tr>
<td><strong>Chemicals, Peptides, and Recombinant Proteins</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Phe-Arg β-naphthylamide dihydrochloride (PAβN)</td>
<td>Sigma-Aldrich</td>
<td>Cat#P4157</td>
</tr>
<tr>
<td>(R)-N-(4-(tert-butyl)thiazol-2-yl)-2-chloro-5-(2,6-diaminohexanamido) benzamide (H-31)</td>
<td>Yamaguchi et al., 2017</td>
<td>N/A</td>
</tr>
<tr>
<td><strong>Critical Commercial Assays</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Quick Ligation™ Kit</td>
<td>New England Biolabs</td>
<td>Cat#M2200</td>
</tr>
<tr>
<td>ClonExpress II One Step Cloning Kit</td>
<td>Vazyme</td>
<td>C112</td>
</tr>
<tr>
<td>iProof High-Fidelity DNA Polymerase</td>
<td>Bio-Rad</td>
<td>Cat#1725301</td>
</tr>
<tr>
<td>Taq DNA polymerase</td>
<td>Thermo Scientific</td>
<td>Cat#EP0406</td>
</tr>
<tr>
<td>RNase Mini Kit</td>
<td>QIAGEN</td>
<td>Cat#74104</td>
</tr>
<tr>
<td>PrimeScript™ RT reagent Kit</td>
<td>Takara</td>
<td>Cat#RR037A</td>
</tr>
<tr>
<td>SYBR™ Green PCR master mix</td>
<td>Applied Biosystems</td>
<td>Cat#4344463</td>
</tr>
<tr>
<td><strong>Oligonucleotides</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Primer list, see Table S6</td>
<td>This paper</td>
<td>N/A</td>
</tr>
<tr>
<td><strong>Recombinant DNA</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Plasmid list, see Table S6</td>
<td>This paper</td>
<td>N/A</td>
</tr>
<tr>
<td><strong>Software and Algorithms</strong></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**LEAD CONTACT AND MATERIALS AVAILABILITY**

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Aixin Yan (ayan8@hku.hk). This study did not generate new unique reagents.

**EXPERIMENTAL MODEL AND SUBJECT DETAILS**

All the bacterial strains used and constructed in this study are listed in Table S6. *E. coli* DH5α is used for plasmid propagation and is usually cultured at 37°C in Luria-Bertani (LB) broth or on the LB agar plate supplemented with 20 μg/ml Kanamycin (KAN). *P. aeruginosa* PA154197 was isolated from the Queen Mary Hospital in Hong Kong, China (Cao et al., 2019). PA154197 and its derivatives were selected on LB agar plate with 500 μg/ml KAN.

**METHOD DETAILS**

**Plasmid Construction**

All the plasmids constructed and used in this study are listed in Table S6. Mini-CRISPR element consisting of two repeats (GTTCACTGCGGTATAGGCAGCTAAGAAA) flanking the spacer (Spacer sequence, see Table S6) was synthesized by BGI (Shenzhen, China). PCR was performed using the iProof High-Fidelity DNA Polymerase (Bio-Rad, USA). Mini-CRISPR elements and plasmid pAYS211 were digested using the restriction enzymes KpnI and *BamH*I (NEB, USA) and ligated using the Quick Ligation™ Kit (NEB, USA). Donor sequences which typically contain 500-bp upstream and 500-bp downstream of the editing sites with 21-bp overlap of the XhoI-digested targeting plasmid at each end (See Donor-Up-F/Donor-Down-R in Table S6) were amplified by PCR and ligated.
Electrocompetent PA154197 cells were prepared by inoculating a fresh colony in LB broth and grown at 37°C overnight with 220-rpm agitation. Following subculture (1:100 dilution) into 50 mL fresh LB broth and growing to OD_{600} = 0.5-0.6, cells were collected by centrifugation at 4°C with 4,500 rpm for 15 min and washed three times with cold, autoclaved Milli-Q H₂O. The resulting cells were resuspended into 1 mL Milli-Q H₂O. 100 μL electrocompetent PA154197 cells were then mixed with 1 μg editing plasmid and subject to electroporation at 2.3 kV (BTX, USA). 1 mL cold LB broth was added to recover the cells. Following recovering at 37°C for 1.5 h with agitation, cells were pelleted and resuspended in 100 μL LB before spread onto the LB plates containing 500 μg/ml KAN. The plates were incubated at 37°C for 24 h.

**Transformation of PA154197**

Electrocompetent PA154197 cells were prepared by inoculating a fresh colony in LB broth and grown at 37°C overnight with 220-rpm agitation. Following subculture (1:100 dilution) into 50 mL fresh LB broth and growing to OD_{600} = 0.5-0.6, cells were collected by centrifugation at 4°C with 4,500 rpm for 15 min and washed three times with cold, autoclaved Milli-Q H₂O. The resulting cells were resuspended into 1 mL Milli-Q H₂O. 100 μL electrocompetent PA154197 cells were then mixed with 1 μg editing plasmid and subject to electroporation at 2.3 kV (BTX, USA). 1 mL cold LB broth was added to recover the cells. Following recovering at 37°C for 1.5 h with agitation, cells were pelleted and resuspended in 100 μL LB before spread onto the LB plates containing 500 μg/ml KAN. The plates were incubated at 37°C for 24 h.

**Mutants Screening and Verification**

Colonies were first subjected to luminescence screening using the Synergy HTX Plate Reader (Bio Tek, USA). Colonies with high luminescent intensity were further verified by colony PCR using Taq DNA polymerase (Thermal Scientific, USA) with indicated primers and DNA sequencing (BGI, China). Sequencing results were visualized using DNA sequencing software Chromas (Technelysium Pty Ltd, Australia).

**Curing of Editing Plasmid**

*P. aeruginosa* cells underwent one round of editing was streaked onto the LB agar plate and incubated at 37°C overnight. Single colony was selected and the curing was verified by the failure of growth in LB broth with 100 μg/ml KAN. In some cases, multiple (2 to 3) rounds of streaking are required for the thorough plasmid curing.

**Antibiotic Sensitivity Assays**

Minimum inhibitory concentration (MIC) was measured in 96-well plate following the standard protocol of ASM with slight modification (Rankin, 2005). Overnight culture was diluted and approximately 10⁵ cells were inoculated in each well containing antibiotic with final concentrations ranging from 0.25 to 128 μg/ml. Following incubation at 37°C for 16-20 h, MIC values were determined as the lowest concentration of antibiotics that completely inhibit growth of bacteria as detected by the unaided eye. Growth measurement shown in Figure 7 was set up in exactly the same manner as the MIC assay, except that cultures were grown at 37°C in the Synergy HTX Plate Reader (Bio Tek, USA) for 12 h with agitation. Cell density (OD_{600}) at 12 h was selected to plot the sensitivity curves. Assays were performed in triplicate.

**Quantitative reverse transcriptase PCR**

Bacterial cells from overnight culture were harvested by centrifugation at 4°C. Total RNA was extracted using RNeasy Mini Kit (QIAGEN, Germany) according to the manufacturer’s instruction. Reverse transcription (RT) was performed using PrimeScript™ RT reagent Kit (Takara, Japan). Quantitative PCR was performed using specific primers and the SYBRTM Green PCR master mix (Applied Biosystems, USA) in a 20 μL reaction system. The reaction was performed in ABI StepOnePlus real time PCR system with recA and clpX as reference genes to normalize the relative expression of the target genes. The results were presented as fold change expression of the target genes, and results were presented as the mean of three independent biological isolates.

**Disk Diffusion Assay**

20 μl overnight culture was mixed with 5 mL melted LB top agar (0.75%) and poured on a LB agar plate. After the agar was solidified, round filter paper disks were placed. 5 μl antibiotic solution (2 mg/ml) was added to the center of the paper disks. The plates were incubated at 37°C for 16 h.

**Fractional Inhibitory Concentration Index**

Synergy of resistance determinants combinations was determined by calculating fractional inhibitory concentration index (FICI) values (Gonzales et al., 2015). The MIC of double or triple reverse mutations is divided by the MIC of each of single mutation, yielding the fractional contribution of each mutation in the combination. Interaction of different resistance mutations (A, B, C) is scored using the following formula: FICI\(_{\text{ABC}}\) = MIC\(_{\text{ABC}}\)/MIC\(_{\text{A}}\)+ MIC\(_{\text{ABC}}\)/MIC\(_{\text{B}}\)+ MIC\(_{\text{ABC}}\)/MIC\(_{\text{C}}\).

**PI-BactD Assay**

Overnight *P. aeruginosa* culture was diluted to OD\(_{600}\) = 0.01 in fresh LB medium in the presence or absence of PA\(_{\text{IN}}\) (7.5 μg/ml). Diluted cell culture was incubated at 37°C with 220-rpm agitation. Cells were harvested when OD\(_{600}\) reaches 2.0 by centrifugation and washed twice using PBS buffer (10 mM, pH 7.2). The bacterial cell pellets were re-suspended in PBS to OD\(_{600}\) as 0.4. PI-BactD was added into 1 mL cell suspension to a final concentration of 10 μM. Output signals of two channels: fluorescence increase (ΔS/S₀) and fluorescence ratiometric changes (I\(_{482}/I_{375}\)) were recorded to plot the 2D graph. Six replicates were conducted for each strain and treatment.
**Time-Kill Assay**

The time-kill assay was performed as described by Mohamed et al. (2014). Briefly, overnight culture of PAO1 or PA154197 was diluted to $1 \times 10^8$ CFU/ml in LB medium and incubated with PAjN (7.5 μg/ml) and antibiotic (IPM or FOF) at certain concentration (4 MIC) at 37°C with 220-rpm agitation. 20 μL of bacterial suspensions were removed at various time intervals (1, 2, 4 h), serially diluted in PBS and plated onto LB agar plates. CFU were counted after 16-20 h incubation at 37°C. Assays were performed in triplicate.

**QUANTIFICATION AND STATISTICAL ANALYSIS**

Experimental replicates and other statistical information can be found in the figure legends. Quantification data presented in the figures are shown as mean ± standard deviation (SD) from three biological replicates where biological replicates ($n = 3$) indicate the numbers of independent, fresh bacterial colonies.

**DATA AND CODE AVAILABILITY**

This study did not generate/analyze [datasets/code].